Alamar Biosciences, Inc. ALMR
27.39 USD 0.00 (+0.00%)
At closeNov 5, 2026, 8:23 AM EST
29.70 +2.31 +8.43%
Pre-market · Nov 5, 8:23 AM ET
25.32 Day range 29.08
18.85 52-week range 39.61
- YTD
- +24.50%
- 1 year
- +24.50%
Analyst view
Price target (mean) 35.40 +29.2% upside
Now 27.39
- Target (low)
- 31.00
- Target (mean)
- 35.40
- Target (high)
- 45.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17322 | -0.24 – -0.13 | 0.00 | 0.0% | 33.12M | 0.0% | 3 |
| Next quarter | -0.23 | -0.23 – -0.23 | 0.00 | 0.0% | 36.33M | 0.0% | 1 |
| Current year | -1.12 | -1.31 – -0.86 | 0.00 | 0.0% | 120.00M | 0.0% | 4 |
| Next year | -0.41574 | -0.90 – -0.12 | -1.12 | +62.9% | 167.01M | +39.2% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 11, 2026 | Stifel | Maintained | Buy | Buy |
| Aug 11, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| May 12, 2026 | Leerink Partners | Initiated | — | Outperform |
| May 12, 2026 | TD Cowen | Initiated | — | Buy |
| May 12, 2026 | JP Morgan | Initiated | — | Overweight |
| May 12, 2026 | Stifel | Initiated | — | Buy |